 |
2003
OMIG, Abstract 15
OMIG
Main Page | 2003
Abstracts | <
Previous | Next>
Comparison
of Fungal Contamination In Benzalkonium Chloride (BAK) Preserved
and BAK Free Fluoroquinolone Antibiotics
M. Rhee, D. Ritterband, M. Shah, W. Perez, T. Kaiura, R. Koplin,
J. Seedor. The New York Eye and Ear Infirmary, New York, New York,
and New York Medical College, Valhalla, NY.
Purpose:
To compare fungal contamination in benzalkonium chloride (BAK) preserved
and BAK free fluoroquinolone antibiotics.
Methods: 5cc aliquots of commercial preparations
of fluoroquinolone antibiotics (CILOXANTM, OCUFLOXTM
QUIXINTM, VIGAMOXTM and ZYMARTM)
were collected in sterile test tubes. Normal saline and thioglycollate
broth were used as the negative and positive controls respectively.
1 x 106 CFU/ml Candida albicans ATCC 10231 were inoculated
into normal saline and turbidity measured by spectrophotometry.
0.1cc of this suspension was then placed in each of the antibiotics
and controls. After vortex mixing, serial dilutions of the specimens
were made (1:10 to 1:1000). The tubes were incubated at 30oC.
After 3 days, subcultures were performed on Sabouraud dextrose agar
(BBL) with a standardized 1uI loop. The plates were incubated at
30oC and subcultures performed on days 1, 7, and 15.
United States Pharmacopeia requirements for Antimicrobial Effectiveness
Testing were followed.
Results: At days 1, 7, and 15, the colonies in
both the normal saline and thioglycollate broth controls were too
numerous to count although qualitatively, there were many more colonies
in the thioglycollate. At day 7, there was a small increase in the
number of CFUs above that anticipated by the serial dilutions in
CILOXAN and QUIXIN. Similarly, at day 15, slightly higher growth
was noted in CILOXAN and OCUFLOX. No other specimens revealed an
increase in the number of CFUs above that anticipated by the serial
dilutions; no specimens had fewer CFUs.
Conclusions: No significant difference was found
in fungal growth between BAK preserved (CILOXAN , OCUFLOX, QUIXIN,
ZYMAR) and BAK free (VIGAMOX) fluoroquinolone antibiotics over the
course of the study. These results are reassuring in that there
does not appear to be an increased risk of fungal contamination
in this particular BAK free antibiotic. BAK free preparations may
be beneficial in patients with ocular surface disease or following
surgical procedures where BAK might be particularly detrimental.
Whether other fluoroquinolone antibiotics would prevent growth of
C.albicans in the absence of BAK is unknown.
OMIG
Main Page | 2003
Abstracts | <
Previous | Next>
|
|
|
